Feature | June 06, 2013

Impact of Sequestration on the National Institutes of Health

NIH says every area of research will be impacted with $1.55 billion in budget cuts


June 6, 2013 — The National Institutes of Health (NIH), the nation’s medical research agency and the leading supporter of biomedical research in the world, said all of its clinical programs will be effected by $1.55 billion in NIH budget cuts due to sequestration. On March 1, 2013, as required by statute, President Obama signed an order initiating sequestration. This requires NIH to cut 5 percent, or $1.55 billion, of its fiscal year (FY) 2013 budget. NIH must apply the cut evenly across all programs, projects and activities (PPAs), which are primarily NIH institutes and centers. 

More than 80 percent of the NIH's budget goes to over 300,000 research personnel at more than 2,500 universities and research institutions throughout the United States. In addition, about 6,000 scientists work in NIH’s own Intramural Research laboratories, most of which are on the NIH main campus in Bethesda, Md. The main campus is also home to the NIH Clinical Center, the largest hospital in the world totally dedicated to clinical research.

The Estimated Numbers

In comparing FY 2013 figures to FY 2012, NIH has arrived at the following estimates for cuts.

  • Approximately 700 fewer competitive research project grants issued
  • Approximately 750 fewer new patients admitted to the NIH Clinical Center
  • No increase in stipends for National Research Service Award recipients in FY2013

 

The Impact of Cuts

NIH said the cuts will delay medical research progress. Medical breakthroughs do not happen overnight, NIH said.  In almost all instances, breakthrough discoveries result from years of incremental research to understand how disease starts and progresses. Even after the cause and potential drug target of a disease is discovered, NIH said it takes on average 13 years and $1 billion to develop a treatment for that target.

Therefore, cuts to research are delaying progress in medical breakthroughs, including:

  • Development of better cancer drugs that zero in on a tumor with fewer side effects,
  • Research on a universal flu vaccine that could fight every strain of influenza without needing a yearly shot, and
  • Prevention of debilitating chronic conditions that are costly to society and delay development of more effective treatments for common and rare diseases affecting millions of Americans.

 

Reductions to noncompeting research project grants (RPG) vary. The NIH-wide average is -4.7 percent.

Institutes and centers have flexibility to accommodate the new budget level in a fashion that allows them to meet their scientific and strategic goals. As noted above, there are different percentages for different Institutes and Centers (ICs), and in some cases for different mechanisms within an IC (RPGs, Centers, etc.). In addition, there may be reductions to grants for reasons other than sequestration, as is the case every year.

The impact on NIH’s intramural research at its Bethesda, Md., campus and off-campus facilities is substantial, NIH said. This is because it applies retroactively to spending since Oct. 1, 2012. That can double the effect — a full year’s cut has to be absorbed in less than half a year.

There are no current plans to furlough or cut employees. At present, HHS is pursuing non-furlough administrative cost savings such as delayed/forgone hiring and reducing administrative services contracts so that furloughs and layoffs can be avoided. Additionally, employee salaries at NIH make up a very small percentage (only 7 percent) of the NIH budget.

Approximately 750 fewer new patients will be admitted to the NIH Clinical Center hospital in 2013 or a decrease from 10,695 new patients in 2012 to approximately 9,945 new patients in 2013. While much of this decrease is due to funding, clinical activity is always a dynamic situation with multiple drivers.

For more information: www.nih.gov


Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now